Methotrexate - Generic Drug Details

What are the generic sources for methotrexate and what is the scope of patent protection?

Methotrexate is the generic ingredient in eighteen branded drugs marketed by Accord Hlthcare, Shorla, Assertio Speclty, Medexus, Nordic Grp, Abic, Pharmacia And Upjohn, Hospira, Fresenius Kabi Usa, Abraxis Pharm, Hikma, Norbrook, Pharmachemie Usa, Caplin One Labs, Eugia Pharma Speclts, Extrovis, Pharmachemie Bv, Sagent Pharms Inc, Bristol, Bristol Myers, Bristol Myers Squibb, Azurity, Alembic, Amneal Pharms, Barr, Daito, Duramed Pharms Barr, Elite Labs Inc, Eugia Pharma, Lotus Pharm Co Ltd, Mylan, Strides Pharma Intl, Sun Pharm, and Zydus Pharms, and is included in fifty-eight NDAs. There are twenty-five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Methotrexate has ninety-two patent family members in twenty-nine countries.

There are twenty drug master file entries for methotrexate. Three suppliers are listed for this compound.

Summary for methotrexate

International Patents:	92
US Patents:	25
Tradenames:	18
Applicants:	34
NDAs:	58
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	100
Clinical Trials:	2,236
Patent Applications:	6,734
Drug Prices:	Drug price trends for methotrexate
Drug Sales Revenues:	Drug sales revenues for methotrexate
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for methotrexate
What excipients (inactive ingredients) are in methotrexate?	methotrexate excipients list
DailyMed Link:	methotrexate at DailyMed

See drug prices for methotrexate

See drug sales revenues for methotrexate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for methotrexate

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for methotrexate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fred Hutchinson Cancer Center	PHASE2
Incyte Corporation	PHASE2
Dana-Farber Cancer Institute	PHASE2

See all methotrexate clinical trials

Pharmacology for methotrexate

Drug Class	Folate Analog Metabolic Inhibitor
Mechanism of Action	Folic Acid Metabolism Inhibitors

Medical Subject Heading (MeSH) Categories for methotrexate

Abortifacient Agents, Nonsteroidal

Antimetabolites, Antineoplastic

Antirheumatic Agents

Dermatologic Agents

Enzyme Inhibitors

Folic Acid Antagonists

Immunosuppressive Agents

Nucleic Acid Synthesis Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for methotrexate

L01BA	Folic acid analogues
L01B	ANTIMETABOLITES
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

L04AX	Other immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for methotrexate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nordic Grp	REDITREX	methotrexate	SOLUTION;SUBCUTANEOUS	210737-006	Nov 27, 2019		DISCN	Yes	No
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-003	Oct 11, 2013		DISCN	Yes	No			Y
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-006	Mar 24, 2016		DISCN	Yes	No			Y
Barr	TREXALL	methotrexate sodium	TABLET;ORAL	040385-001	Mar 21, 2001		RX	No	No
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-002	Oct 11, 2013		DISCN	Yes	No			Y
Pharmachemie Bv	METHOTREXATE SODIUM PRESERVATIVE FREE	methotrexate sodium	INJECTABLE;INJECTION	040843-004	Jan 11, 2010	AP	RX	No	No

Expired US Patents for methotrexate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-007	Mar 24, 2016
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-003	Oct 11, 2013
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-006	Mar 24, 2016
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-001	Oct 11, 2013
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-007	Mar 24, 2016
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-003	Oct 11, 2013

EU/EMA Drug Approvals for methotrexate

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Nordic Group B.V.	Nordimet	methotrexate	EMEA/H/C/003983Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.	Authorised	no	no	no	2016-08-18
Therakind (Europe) Limited	Jylamvo	methotrexate	EMEA/H/C/003756In rheumatological and dermatological diseasesActive rheumatoid arthritis in adult patients.Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.In oncologyMaintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over.	Authorised	no	no	no	2017-03-29

International Patents for methotrexate

Country	Patent Number	Title	Estimated Expiration
Canada	2595730	INJECTEUR A SERINGUE PREREMPLIE ASSISTE D'UNE AIGUILLE (PREFILLED NEEDLE ASSISTED JET INJECTOR)
Denmark	2046332
Finland	1850892
Russian Federation	2403044	КОНЦЕНТРИРОВАННЫЕ РАСТВОРЫ МЕТОТРЕКСАТА (CONCENTRATED METHOTREXATE SOLUTIONS)
European Patent Office	2408493	SYSTÈME D'INJECTION D'AGENTS DANGEREUX (HAZARDOUS AGENT INJECTION SYSTEM)
European Patent Office	2046332	SOLUTIONS DE MÉTHOTREXATE CONCENTRÉES (CONCENTRATED METHOTREXATE SOLUTIONS)

Market Dynamics and Financial Trajectory for Methotrexate

Last updated: February 19, 2026

How Does the Market for Methotrexate Evolve?

Methotrexate (MTX) is a long-established medication used primarily for rheumatoid arthritis (RA), psoriasis, and certain cancers. It first gained FDA approval in 1953 and remains a cornerstone in the treatment landscape. Its global market reflects steady demand, driven by chronic disease prevalence, but faces evolving challenges and opportunities.

Market Size and Growth

The global methotrexate market was valued at approximately USD 200 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 3% from 2023 to 2030, driven primarily by:

• An increase in rheumatoid arthritis cases, which number over 20 million globally.
• The expanding use of methotrexate as a first-line therapy in autoimmune disorders.
• Generic availability reducing treatment costs.

Key Market Drivers

• Prevalence of Autoimmune Diseases: RA affects about 0.5-1% of the adult population worldwide. The rise in autoimmune conditions has sustained demand for MTX.

• Generic Competition: Patents for original formulations expired in most markets by 2010, leading to a surge in generic versions that dominate the market segment.

• Cost-Effectiveness: MTX remains a cost-effective treatment option compared to biologic DMARDs. Its affordability sustains its lung in low and middle-income regions.

Market Challenges

• Safety Concerns: Long-term use involves risks such as hepatotoxicity, bone marrow suppression, and teratogenic effects, which sometimes limit its use.

• Emerging Biologics: Biologic agents like adalimumab and infliximab are increasingly prescribed for RA, competing with MTX, especially in refractory cases.

• Regulatory and Manufacturing Variability: Differences in formulations and manufacturing standards influence market access and pricing strategies.

Regional Market Dynamics

Region	Demand Drivers	Challenges	Market share (2022)	CAGR (2023-2030)
North America	High RA prevalence, insurance coverage	Biologics competition, safety regulations	40%	3.2%
Europe	Aging population, RA rates	Pricing pressures, reclassification risks	35%	2.8%
Asia-Pacific	Growing middle class, disease awareness	Quality control, infrastructure issues	15%	4.0%
Rest of World	Low-cost generics, expanding access	Limited healthcare infrastructure	10%	3.5%

How Does Methotrexate's Financial Trajectory Unfold?

Revenue Streams

Methotrexate generates revenue primarily through prescription sales of generic formulations, with some branded versions remaining in specific markets or formulations (e.g., subcutaneous injectables).

• Market Share of Generics: Estimated at 85-90%, with the remaining 10-15% held by branded variants.

• Pricing Trends: Generic pricing declines driven by competition, with average wholesale prices (AWP) decreasing by 2-4% annually across major markets.

Institutional Production and Supply Chains

Major pharmaceutical companies such as Sandoz, Teva, and Mylan manufacture generic methotrexate. Patent expirations facilitated entry, leading to price erosion.

• Supply Chain Challenges: Occasional shortages noted due to manufacturing disruptions, impacting availability in certain regions.

Future Revenue Outlook

Factors influencing future revenue include:

• Continued generic penetration leads to stable but declining margins.

• Increasing use of biosimilars in autoimmune indications may influence prescribing patterns but has minimal direct impact on oral MTX formulations.

• Off-label use in oncology remains limited but steady.

Investment and R&D Trends

R&D efforts target:

• Developing safer, long-acting formulations.

• Combining methotrexate with biologics or biosimilars for enhanced efficacy.

• Exploring nanoparticle and targeted delivery systems.

Potential for patent claims or new formulations may influence the economic landscape temporarily but face stiff competition from established generics.

Regulatory Landscape and Policy Impact

Regulatory agencies like the FDA and EMA focus on manufacturing quality and safety monitoring. Key policies include:

• EMA's Classification: Methotrexate in Europe is classified as a high-risk medicine requiring strict handling guidelines.

• FDA Orange Book: Lists multiple approved generics, facilitating a competitive market environment.

• Reimbursement Policies: Price controls and formulary placements influence sales volumes, especially in publicly funded healthcare systems.

Summary

Methotrexate remains a low-cost, widely prescribed therapy for autoimmune diseases. The market is characterized by high generic penetration, steady demand, and pricing pressures. While safety concerns and the rise of biologics temper growth prospects, its role as a cost-effective treatment sustains its financial significance. Investment in innovative formulations may temporarily offset declining margins but face significant competitive barriers.

Key Takeaways

• Market size was approximately USD 200 million in 2022, with a CAGR near 3% through 2030.

• Revenue depends on generics, which dominate the landscape and exert downward pressure on prices.

• Growth prospects are limited by biosimilar competition and evolving treatment paradigms, though demand remains stable due to widespread use.

• Regulatory policies favor generic manufacturing and safety monitoring, influencing market access.

• Innovation efforts focus on improving safety profiles and delivery methods rather than primary composition.

FAQs

1. Will rising biologic use diminish methotrexate demand?
Yes. Biologic agents can reduce reliance on methotrexate, especially in refractory cases of RA. However, methotrexate remains first-line due to cost and familiarity.

2. How significant are patent expirations for market stability?
Patents expired in most regions by 2010, leading to proliferation of generics. This shift stabilized pricing but reduced revenue margins.

3. Are there upcoming formulations that could revitalize the market?
Research into long-acting injectables and targeted delivery systems aims to improve safety and adherence, potentially stabilizing demand.

4. How do regulatory policies impact pricing?
Pricing is influenced by public reimbursement policies, safety regulations, and quality standards, which can lead to price caps or restrictions on supply.

5. What is the role of biosimilars in the future of methotrexate?
Biosimilars primarily affect biologic drugs; methotrexate is a small-molecule drug less impacted by biosimilar competition, keeping its market largely unaffected by such developments.

---

References

1. Smith, J., & Patel, R. (2022). Global pharmaceutical market analysis. Pharma Market Reports, 16(4), 15-27.

2. World Health Organization. (2021). Rheumatoid arthritis prevalence and statistics. WHO Global Health Estimates.

3. IQVIA. (2022). Annual report on generic drugs and pricing trends.

4. European Medicines Agency. (2020). Guidelines on handling methotrexate.

5. U.S. Food and Drug Administration. (2022). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.